These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 35220832)

  • 1. Recent advances in targeted drug delivery for the treatment of pancreatic ductal adenocarcinoma.
    Song H; Jiang C
    Expert Opin Drug Deliv; 2022 Mar; 19(3):281-301. PubMed ID: 35220832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gradient tumor microenvironment-promoted penetrating micelles for hypoxia relief and immunosuppression reversion in pancreatic cancer treatment.
    Luo Y; Li C; Zhang Y; Liu P; Chen H; Zhao Z; Wang Y; Zhou Z; Song H; Su B; Li C; Li X; Zhang T; You H; Wu Y; Tian Z; Zhang S; Guo Y; Fan H; Chen Q; Jiang C; Sun T
    Acta Biomater; 2023 Sep; 167():387-400. PubMed ID: 37276955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts.
    Liu H; Shi Y; Qian F
    Adv Drug Deliv Rev; 2021 May; 172():37-51. PubMed ID: 33705881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
    Chandana S; Babiker HM; Mahadevan D
    Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment.
    Tarannum M; Vivero-Escoto JL
    Adv Drug Deliv Rev; 2022 Aug; 187():114357. PubMed ID: 35605679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
    Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
    Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Advances in Well-Designed Therapeutic Nanosystems for the Pancreatic Ductal Adenocarcinoma Treatment Dilemma.
    Yang XY; Lu YF; Xu JX; Du YZ; Yu RS
    Molecules; 2023 Feb; 28(3):. PubMed ID: 36771172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
    Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
    Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survival.
    Urbanova M; Cihova M; Buocikova V; Slopovsky J; Dubovan P; Pindak D; Tomas M; García-Bermejo L; Rodríguez-Garrote M; Earl J; Kohl Y; Kataki A; Dusinska M; Sainz B; Smolkova B; Gabelova A
    Biomed Pharmacother; 2023 Sep; 165():115179. PubMed ID: 37481927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the potential of exosomes in diagnosis and drug delivery for pancreatic ductal adenocarcinoma.
    Xu B; Chen Y; Peng M; Zheng JH; Zuo C
    Int J Cancer; 2023 Jan; 152(2):110-122. PubMed ID: 35765844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutrophils in pancreatic ductal adenocarcinoma: bridging preclinical insights to clinical prospects for improved therapeutic strategies.
    Jin Y; Christenson ES; Zheng L; Li K
    Expert Rev Clin Immunol; 2024 Aug; 20(8):945-958. PubMed ID: 38690749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Paradoxical Web of Pancreatic Cancer Tumor Microenvironment.
    Lafaro KJ; Melstrom LG
    Am J Pathol; 2019 Jan; 189(1):44-57. PubMed ID: 30558722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanodiamond Mediated Molecular Targeting in Pancreatic Ductal Adenocarcinoma: Disrupting the Tumor-stromal Cross-talk, Next Hope on the Horizon?
    Singh M; Pal P; Dutta RS; Marbaniang D; Ray S; Mazumder B
    Curr Cancer Drug Targets; 2023; 23(8):620-633. PubMed ID: 36843367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future.
    Christenson ES; Jaffee E; Azad NS
    Lancet Oncol; 2020 Mar; 21(3):e135-e145. PubMed ID: 32135117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel systemic treatment approaches for metastatic pancreatic cancer.
    Dorman K; Heinemann V; Kobold S; von Bergwelt-Baildon M; Boeck S
    Expert Opin Investig Drugs; 2022 Mar; 31(3):249-262. PubMed ID: 35114868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma.
    Al Haddad AH; Adrian TE
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1499-515. PubMed ID: 25078674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing pancreatic cancer immunotherapy: Leveraging localized delivery strategies through the use of implantable devices and scaffolds.
    Minaei E; Ranson M; Aghmesheh M; Sluyter R; Vine KL
    J Control Release; 2024 Sep; 373():145-160. PubMed ID: 38996923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment.
    Zhu YH; Zheng JH; Jia QY; Duan ZH; Yao HF; Yang J; Sun YW; Jiang SH; Liu DJ; Huo YM
    Cell Oncol (Dordr); 2023 Feb; 46(1):17-48. PubMed ID: 36367669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Aggressive Fibroblasts to Enhance the Treatment of Pancreatic Cancer.
    Yu Y; Schuck K; Friess H; Kong B
    Expert Opin Ther Targets; 2021 Jan; 25(1):5-13. PubMed ID: 33246383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Immunological Glance on Pancreatic Ductal Adenocarcinoma.
    Melzer MK; Arnold F; Stifter K; Zengerling F; Azoitei N; Seufferlein T; Bolenz C; Kleger A
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.